Por motivos de mantenimiento se ha deshabilitado el inicio de sesión temporalmente. Rogamos disculpen las molestias.

Mostrar el registro sencillo del ítem

Artículo

dc.creatorLebrón Romero, José Antonioes
dc.creatorLópez López, Manueles
dc.creatorGarcía Calderón, Clara Beatrizes
dc.creatorValle Rosado, Ivánes
dc.creatorRomero Balestra, Fernandoes
dc.creatorHuertas Sánchez, Pabloes
dc.creatorRodik, Roman Ves
dc.creatorKalchenko, Vitaly I.es
dc.creatorBernal Pérez, Evaes
dc.creatorMoyá Morán, María Luisaes
dc.creatorLópez-Cornejo, María del Pilares
dc.creatorOstos Marcos, Francisco Josées
dc.date.accessioned2021-08-30T09:43:01Z
dc.date.available2021-08-30T09:43:01Z
dc.date.issued2021-08
dc.identifier.citationLebrón Romero, J.A., López López, M., García Calderón, C.B., Valle Rosado, I., Romero Balestra, F., Huertas Sánchez, P.,...,Ostos Marcos, F.J. (2021). Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery. Pharmaceutics, 13 (8), 1250.
dc.identifier.issn1999-4923es
dc.identifier.urihttps://hdl.handle.net/11441/125213
dc.description.abstractThe formation of calixarene-based liposomes was investigated, and the characterization of these nanostructures was carried out using several techniques. Four amphiphilic calixarenes were used. The length of the hydrophobic chains attached to the lower rim as well as the nature of the polar group present in the upper rim of the calixarenes were varied. The lipid bilayer was formed with one calixarene and with the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOPE. The cytotoxicity of the liposomes for various cell lines was also studied. From the results obtained, the liposomes formed with the least cytotoxic calixarene, (TEAC12)4, were used as nanocarriers of both nucleic acids and the antineoplastic drug doxorubicin, DOX. Results showed that (TEAC12)4/DOPE/p-EGFP-C1 lipoplexes, of a given composition, can transfect the genetic material, although the transfection efficiency substantially increases in the presence of an additional amount of DOPE as coadjuvant. On the other hand, the (TEAC12)4/DOPE liposomes present a high doxorubicin encapsulation efficiency, and a slow controlled release, which could diminish the side effects of the drug.es
dc.description.sponsorshipEspaña. Consejería de Conocimiento, Innovación y Universidades de la Junta de Andalucía (FQM-206, FQM-274, and PY20-01234)es
dc.description.sponsorshipVI Plan Propio Universidad de Sevilla (PP2019/00000748), RTI2018-100692-B-100; P18-RT-1271; PI18-0005-2018; VI-PP AY.SUPLEM2019; RYC-2015-18670es
dc.description.sponsorshipEspaña Ministry of Science and Innovation-Agencia Estatal de Investigación/10.13039/501100011033 (P.H.) R+D+I grant PID2019-104195Ges
dc.formatapplication/pdfes
dc.format.extent26 p.es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofPharmaceutics, 13 (8), 1250.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcationic calix[4]areneses
dc.subjectliposomeses
dc.subjectnucleic acidses
dc.subjecttransfection efficiencyes
dc.subjectdoxorubicines
dc.subjectencapsulationes
dc.titleMultivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Deliveryes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química Físicaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Genéticaes
dc.relation.projectID(FQM-206, FQM-274, and PY20-01234)es
dc.relation.projectID(PP2019/00000748), RTI2018-100692-B-100; P18-RT-1271; PI18-0005-2018; VI-PP AY.SUPLEM2019; RYC-2015-18670es
dc.relation.projectID10.13039/501100011033 (P.H.) R+D+I grant PID2019-104195Ges
dc.relation.publisherversionhttp://dx.doi.org/10.3390/pharmaceutics13081250es
dc.identifier.doi10.3390/pharmaceutics13081250es
dc.journaltitlePharmaceuticses
dc.publication.volumen13es
dc.publication.issue8es
dc.publication.endPage1250es

FicherosTamañoFormatoVerDescripción
pubpharmaceutics-13-01250-v2.pdf7.740MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional